Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (4 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 102 records in scope (CR5), not by the ranked leaders only.
This landscape tracks patent families combining depth filtration hardware — depth filters, surge vessels, flow-balancing and diversion-valve control — with continuous or semi-continuous clarification workflows in bioprocessing. The scope spans 102 published records filed between 2015 and the 2026 data cut-off, drawn from IPC classes covering separation processes, bioreactors and cell-culture harvesting. Publication lags filing by roughly 18 months, so the final one or two years in any trend chart will always look thinner than they eventually turn out to be.
The records cluster heavily around cell-culture harvest and clarification steps upstream of downstream purification, rather than around filter media chemistry itself. That skew shows up directly in the IPC composition: bioreactor and microorganism classes dominate, while classical separation-process classifications are a minority presence.
Two views of the same 102-record set: how filing activity has moved year over year, and which IPC subclasses the records sit in. Because a single record can carry several IPC codes, the subclass shares below add up to well over 100% of the record total — that is expected, not an error.
Filings ran from 7 in 2017 up to a peak of 10 in 2022, then eased to 2 by 2024 — a -50% move from 2021's 4 filings. 2025 and 2026 are still filling in under the publication lag and should not be read as a drop-off yet.
C12M (bioreactors, 80.4% of records) and C12N (microorganisms, 79.4%) dominate, with C12P fermentation close behind at 71.6%. B01D — the separation-process class that names the filtration hardware directly — appears in only 25.5% of records, meaning most claims are framed around the bioprocess workflow rather than the filter media itself.
Shares are the percentage of the 102 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about depth filtration continuous clarification and every answer comes back with the patent numbers behind it.
Try EurekaThe present disclosure relates to hollow fiber tangential flow filter units, including hollow fiber tangential flow depth filter units, for various applications, including bioprocessing and pharmaceutical applications, systems employing such filters, and methods of filtration using the same.Filed by Repligen, published 2022-10-20.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2015188009A1 | Methods for harvesting mammalian cell cultures | 45 |
| 2 | GB2385008A | Surface Microfilter | 20 |
| 3 | GB2385008B | Surface microfilters | 5 |
| 4 | US11339775B2 | Alternating tangential flow rapid harvesting | 4 |
| 5 | US11384378B2 | Methods for harvesting mammalian cell cultures | 4 |
| 6 | WO2015188009A9 | Methods for harvesting mammalian cell cultures | 4 |
| 7 | US20180148677A1 | Alternating Tangential Flow Rapid Harvesting | 3 |
| 8 | US20230332201A1 | Cell culture methods for antibody production | 1 |
| 9 | US20220356502A1 | Methods for harvesting mammalian cell cultures | 1 |
| 10 | WO2022221410A1 | Systems and methods for tangential flow depth filtration | 1 |
Citation counts favour older records simply because they have had more time to accumulate them — read this as a signal of influence within the corpus, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three findings that shape where to file, where to watch, and where a design-around is actually available.
With a single assignee holding 62 of the 102 records and the top five holding 92, this is not a landscape where a new entrant can quietly file adjacent claims and expect white space by default. Any freedom-to-operate review has to clear the leading portfolio first.
Filing activity peaked at 10 records in 2022 and had fallen to 2 by 2024, a -50% move over that span. Given the 18-month publication lag, 2025-2026 figures are not yet reliable evidence of a continued decline.
Most records are classified under bioreactor and microorganism codes (C12M, C12N) rather than the separation-process class B01D. Claims are being written around the continuous-clarification workflow — surge vessels, flow balancing, valve switching — more than around depth-filter media composition itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to depth filtration continuous clarification, with the prior art for and against each one.
Sixteen assignees make up the entire ranked field returned by the data endpoint — this is not a top-50 or top-100 cut, it is the whole list. Momentum across the recent-year window has flattened for the named leaders, several showing 0 filings in the latest year.
One assignee holds 62 of the 102 records in scope, well ahead of the fifth-place holder at 2 records. Any competitive read of this space starts with that portfolio's claim scope, not with the long tail below it.
The top 10 combined hold 97.1% of all 102 records, leaving only a handful of records spread across the remaining ranked entrants. New filers face a landscape where most adjacent claim space is already occupied by a small group.
Several of the leading assignees recorded zero filings in the latest year tracked, with year-over-year drops of -100% for at least two of them. That reads as filing quiet rather than retreat, given the publication lag on the most recent cohort.
| Assignee | Recent year | YoY |
|---|---|---|
| Amgen Inc. | 0 | -100% |
| Repligen Corporation | 0 | — |
| Regeneron Pharmaceuticals Inc. | 0 | -100% |
| IGI Therapeutics SA | 0 | — |
| Bristol Myers Squibb Co. | 0 | — |
| Graver Co. | 0 | — |
| HOLDICH RICHARD G | 0 | — |
| CUMMING IAIN W | 0 | — |
The dataset points to specific next steps rather than general monitoring.
Before filing in continuous clarification, map the claim scope of the single assignee holding 62 of the 102 records — it sets the practical boundary for what remains open.
Run a freedom-to-operate checkPositive-displacement pump integration and automated valve-control logic show thin claim density relative to the harvest-and-clarification core — worth a closer prior-art pull before drafting.
Explore white space in EurekaThe last two years in the trend chart understate true filing activity because of publication lag; re-run this landscape in a year to see the corrected 2024-2025 picture.
Set a monitoring alertOne assignee holds 62 of the 102 records in scope, making it by far the largest portfolio in this dataset. The next four assignees together bring the top-five total to 92 records, or 90.2% of everything in scope. Below that, filing activity drops sharply across the remaining ranked entrants, so competitive analysis in this space should weight the leading portfolio heavily rather than treating filers as roughly equal.
Filing activity peaked at 10 records in 2022 and had fallen to 2 by 2024, a -50% change over that three-year span. Because patent publication lags filing by roughly 18 months, the 2025 and 2026 figures in any trend chart are still incomplete and should not be read as confirmation of a continued decline. The honest read is that the field cooled from its 2022 peak, with the most recent trajectory still unresolved.
Bioreactor and cell-culture classes (C12M and C12N) appear in roughly 80% of the 102 records each, with fermentation-related C12P close behind at 71.6%. Classical separation-process classification (B01D), which covers filtration hardware directly, appears in only 25.5% of records. That pattern shows most claims are framed around the bioprocess harvest workflow — surge vessels, flow balancing, valve switching — rather than around filter media or membrane chemistry itself.
The evidence points to a few specific under-claimed branches: positive-displacement pump integration, body-fluid-contact filtration device configurations, and automated diversion-valve control logic all show thin representation relative to the dominant harvest-and-clarification cluster. These are narrower classes in the IPC composition data, not confirmed gaps, so any filing decision there still needs a targeted prior-art search rather than relying on the aggregate figures alone.
WO2022221410A1, filed by Repligen and published in October 2022, covers hollow fiber tangential flow filter units — including tangential flow depth filter configurations — for bioprocessing and pharmaceutical filtration systems. It is the representative filing for this landscape because it sits squarely in the tangential-flow depth filtration mechanism that much of the surrounding claim activity builds around. Anyone designing hardware in this space should treat it as a reference point for how broadly tangential-flow depth filter claims can be drafted, though a full clearance requires reading the granted claims themselves, not just the abstract.
With the top five assignees holding 90.2% of all 102 records and the top ten holding 97.1%, this field sits at the highly concentrated end of the spectrum. Only 16 assignees appear in the ranked list at all, and the gap between the leader's 62 records and the fifth-place holder's 2 records is stark. That level of concentration means new entrants are more likely to find room in adjacent, under-claimed technical branches than in the core harvest-and-clarification claim space itself.
Go past this page: query the whole depth filtration continuous clarification corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.